A UCLH patient has received an innovative treatment for radiotherapy-induced dry mouth, an irreversible serious adverse effect of head and neck cancer radiotherapy that causes permanent impairment of talking and eating.
UCLH has recruited the first participant to a global study of a new drug in early development, which is thought to reduce the production of a protein in the brain called tau.
A UCLH patient is the first person in the UK to receive a new investigational drug being tested for a disorder caused by genetic mutations, called classic congenital adrenal hyperplasia.
UCLH has recruited the first UK participant to a trial of a new immunotherapy drug for patients with advanced solid cancers who no longer respond to existing treatments.
A potential new drug for patients with multiple myeloma who have failed to respond to several rounds of existing treatments has shown promise in an early phase trial at UCLH.